Cell and gene therapies, as well as viral vaccines, need higher production yields—and that's where we excel. We significantly increase yields by targeting the innate cellular defenses within production cells. These natural defenses, designed to combat foreign genetic material and inhibit viral replication, can hinder your process. Our solution is a unique panel small molecules which make up our Viral Sensitizer (VSETM) platform, which dampen cellular defenses.
Using an innovative high-throughput screening process, we have developed a library of novel VSEs. Virica continues to leverage this advanced technology to pinpoint the most synergistic Viral Sensitizer molecules from our library, tailored to any virus or cell line. We customize formulations of these Viral Sensitizers to enhance virus yield in your manufacturing process or optimize the effectiveness of your viral therapies. The result is higher yields and improved quality, helping to reduce costs and improve patient access.
Company Details
- Employees
- 40
- Founded
- -
- Address
- 7 Bayview Station Rd, Ottawa,ontario K1y 2c5,canada
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- viricabiotech.com
- HQ
- Ottawa, Ontario
Virica Biotech Questions
Virica Biotech's website is viricabiotech.com
Virica Biotech's LinkedIn profile is https://ca.linkedin.com/company/virica
Virica Biotech has
40 employees.
View email and phone details for 40
employees at Virica Biotech.
Virica Biotech's industry is
Biotechnology Research
Virica Biotech's top competitors are
Ccrm,
Omniabio,
Biotecanada,
Oncolytics Biotech Inc.,
Biotalent Canada,
Notch Therapeutics,
Kane Biotech Inc.,
Stemcell Technologies,
Bluerock Therapeutics,
Biovectra.
Virica Biotech's categories are Biotechnology Research
Virica Biotech's founding year is 2018
